| Literature DB >> 34104234 |
Florica Sandru1,2, Mara Carsote3,4, Simona Elena Albu5,6, Mihai Cristian Dumitrascu5,6, Ana Valea7,8.
Abstract
Vitiligo, the discoloration of the skin, has different autoimmune mechanisms reflected by many biomarkers as shown by skin histology, staining for CD4 and CD8 T lymphocytes, chemokine ligand 9 or circulating cytokines such as interleukin (IL)-1 beta, interferon (IFN)-gamma, transforming growth factor (TGF)-beta, antibodies, markers of oxidative stress, chemokines, and others. In this narrative review, we aim to overview vitiligo in relationship with chronic autoimmune thyroiditis. Regarding vitiligo, more than 50 different genetic loci have been associated with this disease, and the heritability is high. There is a 20% risk of an environmental connection which may also act as a trigger; moreover, the association with human leukocyte antigen (HLA) expression is well recognized. The specific lesions display CD8+ tissue-resident memory T cells as continuous key activators of melanocytes. The association with chronic thyroiditis is based on common autoimmune background and excessive reactive oxygen species that destroy melanocytes and thyrocytes (oxidative stress hypothesis) with thyroxine and melanin as target molecules, thus sharing a common origin: tyrosine. Moreover, common epigenetic anomalies or mutations of the Forkhead transcription factor D3 (FOXD3) have been described. Since vitiligo affects up to 1-2% of the population worldwide and 34% of patients have positive thyroid antibodies, apart from common autoimmunity background and oxidative stress toxicity, the association is clinically relevant for different practitioners. ©2021 JOURNAL of MEDICINE and LIFE.Entities:
Keywords: ATG – anti-thyroglobulin antibodies; FOXD3 – forkhead transcription factor D3; IFN – interferon; IL – interleukin; JAK-STAT – Janus kinase-signal transducer and activator of transcription; ROS – reactive oxygen species; TGF – transforming growth factor; TPO – thyroid peroxidase antibodies; antibodies; thyroiditis; vitiligo
Year: 2021 PMID: 34104234 PMCID: PMC8169145 DOI: 10.25122/jml-2019-0134
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X